Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Thromboembolism
Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Identification of the Most Relevant Risk Factors for Thromboembolism
Sponsor: Hellenic Society of Surgical Oncology
Listed as NCT04246073, this observational or N/A phase trial focuses on Cancer and Cancer Diagnosis and remains ongoing. Sponsored by Hellenic Society of Surgical Oncology, it has been updated 6 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2022 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Recruiting
▶ Show 1 earlier version
-
Feb 2020 — Aug 2020 [monthly]
Recruiting
First recorded
Feb 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hellenic Society of Surgical Oncology
For direct contact, visit the study record on ClinicalTrials.gov .